What is ABBV's current stock price?

ABBV is currently trading at $225.37 with a daily change of -1.01%. Visit StocksRunner for live updates.

What are ABBV stock's key strengths?

ABBV current strengths include: Pays a reliable dividend, Investors confidence is positive, Outperform the market, Earnings are forecast to grow, Trading below its fair value. These are updated in real time by the StocksRunner IQ algorithm.

What are the risks associated with ABBV stock?

Current risk factors for ABBV include: Low. Risk levels are assessed by StocksRunner based on volatility, sector strength, volume, and investor confidence.

What is ABBV's current StocksRunner IQ Score?

ABBV current StocksRunner IQ Score is: Strong Buy. This score reflects aggregated earnings data, news sentiment, analyst ratings, and market momentum as of the latest update.

What factors influence ABBV's StocksRunner IQ Score?

ABBV StocksRunner IQ Score is a composite Credibility Score that weighs: quarterly earnings results vs. analyst expectations, breaking news sentiment and headline credibility, Wall Street analyst price target consensus, trading volume and price momentum, and sector-level risk indicators. All factors are aggregated in real time.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

ABBV Stock Analysis & IQ Rating | AbbVie

Q: Should I buy ABBV stock right now?

StocksRunner does not provide personalized investment advice. Our IQ Credibility Score for ABBV aggregates analyst sentiment, earnings performance, and news momentum to help you make an informed decision. The current IQ signal is: Strong Buy. Always consider your own risk tolerance and consult a financial advisor before investing.

Q: What does a Strong Buy rating mean for ABBV?

A Strong Buy rating on StocksRunner indicates that the aggregated IQ score — drawing from earnings beats, analyst upgrades, and positive news sentiment — reflects high confidence in ABBV near-term growth potential. It is the strongest signal in the StocksRunner IQ rating scale.

ABBV

AbbVie

$225.37

-$2.31 | -1.01%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$244.81

MKT CAP

$398.49B

52W Low

$164.39

VOL

$7.54M

P/E Ratio

95.46

AVG VOL

$7.07M

RSI

46.48

TREND

Sideways

ABBV Stock IQ

Login to see AbbVie (ABBV) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

ABBV Target Price

Login to display

Strengths

ABBV Rewards

Earnings are forecast to grow

ABBV Rewards

Trading below its fair value

ABBV Rewards

Pays a reliable dividend

ABBV Rewards

Outperform the market

ABBV Price Performance

$227.5 (-0.94%)

$227.45 (-0.91%)

$226.87 (-0.66%)

$202.72 (+11.17%)

1year

6month

3month

1month

ABBV Analysts Opinion

Overall standing based on market and analyst consensus. menu Hover over the category for more information

ABBV Analysts opinion is positive but there was a setback from the past 3 months

ABBV Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

86%

Consensus Rating

100%

Buy
Opinion

50%

Trend
Score

100%

Potential
Score

ABBV Street Sentiment is extremely bullish and have positive views on the near-term outlook

ABBV Risk Level

ABBV has Low risk level

Low

LOW

HIGH

ABBV Performance Sentiment

Sentiments overview associated with events and the stock performance

86%

Positive

50 out of 58
events present

10%

Negative

6 out of 58
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support Price

$217.11

Resistance Price

$236.19

Current Price Range

$227.68

$217.11

$236.19

Show methods +

Analyst Consensus

Recent Upgrades and Downgrades

75%

Consensus Rating

BUY

6

Buy

2

Hold

0

Sell

Date

Action

Rating

Firm

Feb 23, 2026

Initiate

Overweight

Barclays

Feb 20, 2026

Initiate

Overweight

Barclays

Feb 12, 2026

Reiterate

its Overweight

Cantor Fitzgerald

Jan 27, 2026

Price Target Raised

Buy

Jan 06, 2026

Price Target Raised

Buy

Morgan Stanley

Runners Also Watch

Close Price

Change

PFE

Pfizer

26.86

-1.61%

SNY

Sanofi

43.63

-0.71%

LLY

Eli Lilly and

977.25

-2.26%

MRK

Merck Company

115.91

-0.26%

TEVA

Teva Pharma

29.30

-3.84%

ABBV Latest Analysis +

Market Downturn: 2 Stocks to Buy and Hold Through Any Storm. Key PointsAbbVie can maintain solid financial results even during recessions.

Wed Mar 11, 2026

$227.68 | +0.30%

Earnings

AbbVie Inc. (ABBV) Presents at Leerink Global Healthcare Conference 2026 Transcript.

Tue Mar 10, 2026

$227.01 | -0.19%

Activity

Heres Why AbbVie (ABBV) is a Strong Momentum Stock. The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.

Mon Mar 9, 2026

$227.45 | -1.15%

Momentum

AbbVies Early Obesity Drug Data Shows Up To 10% Weight Loss. AbbVie Inc. (NYSE:ABBV) shares are trading lower on Monday.The United States drug maker shared topline results from a Phase 1 study of ABBV-295 a long-acting amylin analog aimed at treating obesity.In March 2025 AbbVieand Gubra A/S announced a license agreement to develop GUB014295 (ABBV-295).The stock’.s performance comes as the broader market is experiencing some pressure with the S&.P 500 down 0.9% and the Healthcare sector

Mon Mar 9, 2026

$227.45 | -1.15%

Momentum

AbbVie Reports Positive Topline Results In Phase 1 Study For ABBV-295 In Weight Management . (RTTNews) - AbbVie Inc. (ABBV) announced Monday positive topline results from the multiple ascending dose (MAD) part of its Phase 1 study evaluating the safety tolerability pharmacokinetics (PK) and pharmacodynamics (PD) of subcutaneous ABBV-295 in adults with a mean body ma

Mon Mar 9, 2026

$227.45 | -1.15%

Activity

AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohns Disease. AbbVie Inc. (NYSE:ABBV) is one of the best undervalued stocks to invest in right now. AbbVie Inc. (NYSE:ABBV) announced on March 2 positive topline results from the Phase 3 randomized placebo-controlled double-blind AFFIRM study evaluating the efficacy and safety of risankizumab subcutaneous induction treatment versus placebo in adult patients

Mon Mar 9, 2026

$227.45 | -1.15%

Potential

AbbVie Inc. (ABBV) Presents at TD Cowen 46th Annual Health Care Conference Transcript.

Wed Mar 4, 2026

$236.19 | +1.03%

Activity

AbbVie sees positive late-stage results for subcutaneous Skyrizi in Crohns.

Mon Mar 2, 2026

$234.26 | +0.94%

Activity

Is AbbVie Inc. (ABBV) One of the Best Cancer Stocks to Invest In Now?. AbbVie (NYSE:ABBV) is one of the best cancer stocks to invest in now. On February 23 AbbVie (NYSE: ABBV) announced plans to invest $380 million to build two new active pharmaceutical ingredient manufacturing facilities. The new state-of-the-art facilities at the Illinois campus are to integrate advanced manufacturing technologies with artificial intelligence. Artificial intelligence integration is [….]

Mon Mar 2, 2026

$234.26 | +0.94%

Activity

RBC Capital Launches AbbVie (ABBV) Coverage Expects Shares to Outperform Amid Competitive Fears. AbbVie Inc. (NYSE:ABBV) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. On February 25 RBC Capital analyst Trung Huynh initiated coverage of AbbVie Inc. (NYSE:ABBV) with an Outperform rating and a $260 price target. The analyst noted that the shares have lagged due to concerns that AbbVies beat-and-raise story [….]

Thu Feb 26, 2026

$224.69 | -0.98%

Earnings

FAQ About ABBV Stock Insights

What is ABBV current stock price?

What are ABBV stock strengths?

What is ABBV Risk Level?

What is ABBV market cap and volume?

What is ABBV current Stock IQ?

Should I buy ABBV stock right now?

Is ABBV a Strong Buy right now?

What does a 'Strong Buy' rating mean for ABBV?

What does a 'Strong Sell' rating mean for ABBV?

What factors influence ABBV's Stock IQ?

Explore our ABBV Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored ABBV Stock Strategies
Effective Risk Management

FIND US ON

Receive our ABBV Daily Alerts

Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

ABBV

AbbVie

Set Alerts

Current Price

$225.37

-$2.31 | -1.01%

52W High

$244.81

MKT CAP

$398.49B

52W Low

$164.39

VOL

$7.54M

P/E Ratio

95.46

AVG VOL

$7.07M

RSI

46.48

TREND

Sideways

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Runners Also Watch

Symbol

Close

Change

PFE

Pfizer

26.86

-1.61%

SNY

Sanofi

43.63

-0.71%

LLY

Eli Lilly and

977.25

-2.26%

MRK

Merck Company

115.91

-0.26%

TEVA

Teva Pharma

29.30

-3.84%

ABBV Price Performance

$227.5 (-0.94%)

$227.45 (-0.91%)

$226.87 (-0.66%)

$202.72 (+11.17%)

1year

6month

3month

1month

ABBV Analysts Opinion

Overall standing per market and analyst expectations. menu Hover over the category for more information

ABBV Analysts opinion is positive but there was a setback from the past 3 months

ABBV Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

86%

Consensus Rating

100%

Buy
Opinion

50%

Trend
Score

100%

Potential
Score

ABBV Street Sentiment is extremely bullish and have positive views on the near-term outlook

ABBV Risk Level

ABBV has Low risk level

Low

LOW

HIGH

ABBV Performance Sentiment

Sentiments overview associated with events and the stock performance.

86%

Positive

50 out of 58
events present

10%

Negative

6 out of 58
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support Price

$217.11

Resistance Price

$236.19

Current Price Range

$227.68

$217.11

$236.19

Show methods +

Latest Analyst Actions

Overall Wall Street Rating

75%

Consensus Rating

BUY

6

Buy

2

Hold

0

Sell

Date

Action

Rating

Firm

Feb 23, 2026

Initiate

Overweight

Barclays

Feb 20, 2026

Initiate

Overweight

Barclays

Feb 12, 2026

Reiterate

its Overweight

Cantor Fitzgerald

Jan 27, 2026

Price Target Raised

Buy

Jan 06, 2026

Price Target Raised

Buy

Morgan Stanley

ABBV Stock IQ

Login to unlock AbbVie (ABBV) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Target Price

Login to display

Stock Insights

Strengths

ABBV Rewards

Earnings are forecast to grow

ABBV Rewards

Trading below its fair value

ABBV Rewards

Pays a reliable dividend

ABBV Rewards

Outperform the market

ABBV Latest Analysis

Market Downturn: 2 Stocks to Buy and Hold Through Any Storm. Key PointsAbbVie can maintain solid financial results even during recessions.

Wed Mar 11, 2026

$227.68 | +0.30%

Earnings

AbbVie Inc. (ABBV) Presents at Leerink Global Healthcare Conference 2026 Transcript.

Tue Mar 10, 2026

$227.01 | -0.19%

Activity

Heres Why AbbVie (ABBV) is a Strong Momentum Stock. The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.

Mon Mar 9, 2026

$227.45 | -1.15%

Momentum

AbbVies Early Obesity Drug Data Shows Up To 10% Weight Loss. AbbVie Inc. (NYSE:ABBV) shares are trading lower on Monday.The United States drug maker shared topline results from a Phase 1 study of ABBV-295 a long-acting amylin analog aimed at treating obesity.In March 2025 AbbVieand Gubra A/S announced a license agreement to develop GUB014295 (ABBV-295).The stock’.s performance comes as the broader market is experiencing some pressure with the S&.P 500 down 0.9% and the Healthcare sector

Mon Mar 9, 2026

$227.45 | -1.15%

Momentum

AbbVie Reports Positive Topline Results In Phase 1 Study For ABBV-295 In Weight Management . (RTTNews) - AbbVie Inc. (ABBV) announced Monday positive topline results from the multiple ascending dose (MAD) part of its Phase 1 study evaluating the safety tolerability pharmacokinetics (PK) and pharmacodynamics (PD) of subcutaneous ABBV-295 in adults with a mean body ma

Mon Mar 9, 2026

$227.45 | -1.15%

Activity

AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohns Disease. AbbVie Inc. (NYSE:ABBV) is one of the best undervalued stocks to invest in right now. AbbVie Inc. (NYSE:ABBV) announced on March 2 positive topline results from the Phase 3 randomized placebo-controlled double-blind AFFIRM study evaluating the efficacy and safety of risankizumab subcutaneous induction treatment versus placebo in adult patients

Mon Mar 9, 2026

$227.45 | -1.15%

Potential

AbbVie Inc. (ABBV) Presents at TD Cowen 46th Annual Health Care Conference Transcript.

Wed Mar 4, 2026

$236.19 | +1.03%

Activity

Discover ABBV Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of ABBV. We're here to help you make informed investment decisions today.

FIND US ON

Receive our ABBV Daily Alerts

Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

ABBV Stock trends

ABBV Stock performance

ABBV Stock analysis

ABBV investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing ABBV

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing ABBV

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

ABBV Stock Analysis & IQ Rating | AbbVie

ABBV Stock IQ

ABBV Target Price

ABBV Analysts Opinion

ABBV Street Sentiment

ABBV Risk Level

ABBV Performance Sentiment

Key Price Levels

Analyst Consensus

Explore our ABBV Stock insights

Receive our ABBV Daily Alerts

ABBV Street Sentiment

ABBV Risk Level

Key Price Levels

Latest Analyst Actions

Discover ABBV Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of ABBV. We're here to help you make informed investment decisions today.

Receive our ABBV Daily Alerts

ABBV Alerts